Juffermans Jorine H M, Hanssens Patrick E J, van Putten Wim L J, van Rhoon Gerard C, van Der Zee Jacoba
Department of Radiation Oncology, Hyperthermia Unit, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.
Cancer. 2003 Oct 15;98(8):1759-66. doi: 10.1002/cncr.11719.
The objective of this study was to evaluate the palliative effect of reirradiation and hyperthermia in patients with unresectable, recurrent colorectal carcinoma.
The medical records of 54 patients with unresectable, recurrent colorectal carcinoma that caused pain and who were treated with reirradiation and hyperthermia, were evaluated retrospectively. Previous radiotherapy was given up to a total dose ranging from 25-70 grays (Gy). The median interval between prior radiotherapy and reirradiation was 22 months (range, 4-97 months). The total reirradiation dose varied from 24 Gy to 32 Gy given in fractions of 4 Gy twice weekly. Three or four hyperthermia treatments were given once weekly. Toxicity was registered. The influence of World Health Organization (WHO) performance status, maximum tumor dimension, and time between first radiotherapy and reirradiation on therapeutic outcome was evaluated. The results of this study were compared with published results on patients who received radiotherapy with or without hyperthermia.
Forty-seven patients (87%) completed the planned treatment schedule. The maximum toxicity was Grade 2. All patients were evaluated for palliative effect. The median follow-up was 10 months. A good or complete palliative effect was achieved in 72% of patients for a median duration of 6 months. Patients who had a better WHO performance status, smaller tumors, and a longer interval between first radiotherapy and reirradiation had slightly better outcomes, although none of those parameters reached statistical significance.
The described combined treatment was feasible and well tolerated. Comparison of results from radiotherapy plus hyperthermia with results after radiotherapy alone suggested that additional hyperthermia prolonged the duration of palliation. Firm proof of the contribution of hyperthermia will require performing a Phase III study.
本研究的目的是评估再程放疗联合热疗对不可切除的复发性结直肠癌患者的姑息治疗效果。
回顾性评估54例因不可切除的复发性结直肠癌引起疼痛且接受再程放疗联合热疗的患者的病历。先前放疗的总剂量达25至70格雷(Gy)。先前放疗与再程放疗的中位间隔时间为22个月(范围4至97个月)。再程放疗的总剂量为24 Gy至32 Gy,分4 Gy每次,每周两次。每周进行一次三或四次热疗。记录毒性反应。评估世界卫生组织(WHO)体能状态、最大肿瘤直径以及首次放疗与再程放疗之间的时间对治疗结果的影响。将本研究结果与已发表的接受放疗联合或不联合热疗患者的结果进行比较。
47例患者(87%)完成了计划的治疗方案。最大毒性为2级。对所有患者评估姑息治疗效果。中位随访时间为10个月。72%的患者获得了良好或完全的姑息治疗效果,中位持续时间为6个月。WHO体能状态较好、肿瘤较小以及首次放疗与再程放疗间隔时间较长的患者结局略好,尽管这些参数均未达到统计学显著性。
所描述的联合治疗可行且耐受性良好。放疗加用热疗的结果与单纯放疗结果的比较表明,额外的热疗延长了姑息治疗的持续时间。热疗作用的确切证据需要进行III期研究。